Table 3.

Overall survival rates in the study population according to HCC stages and treatment modalities

Treatment			Median overall survival (months)		Overall survival rate (%)
			Before IPTW	After IPTW	1-year	2-year	3-year	4-year	5-year
BCLC stage 0/A
	Surgery
		Elderly	86.3 (77.0-95.6)	97.4 (92.0-102.8)	83.8	81.1	71.9	67.7	65.1
		Non-elderly	133.9 (127.7-140.1)	138.0 (126.1-141.7)	90.9	87.5	83.6	77.2	75.4
	Local ablation therapy
		Elderly	65.9 (50.4-81.4)	82.2 (74.7-89.7)	80.8	73.2	65.3	54.7	50.8
		Non-elderly	127.8 (120.9-134.7)	105.5 (99.1-111.9)	88.0	82.5	79.1	75.1	72.1
	Transarterial therapy
		Elderly	38.5 (36.3-40.7)	42.6 (39.6-45.6)	74.7	62.8	52.8	40.2	36.3
		Non-elderly	85.2 (78.8-91.6)	56.9 (47.6-66.2)	80.9	74.6	67.0	59.8	56.9
BCLC stage B
	Surgery
		Elderly	78.1 (42.5-113.7)	66.0 (52.1-79.9)	82.2	77.7	67.7	57.6	53.0
		Non-elderly	94.3 (79.9-108.7)	90.3 (74.2-106.4)	86.7	80.9	77.8	68.6	64.4
	Transarterial therapy
		Elderly	33.5 (28.5-38.5)	36.5 (33.7-39.3)	70.7	58.9	48.6	36.8	31.6
		Non-elderly	43.6 (36.9-50.3)	37.2 (34.6-39.8)	72.3	65.7	56.8	48.1	43.4
BCLC stage C
	Transarterial therapy
		Elderly	30.5 (25.7-35.7)	28.4 (24.4-32.4)	67.9	56.2	41.9	33.6	28.5
		Non-elderly	32.5 (28.8-36.2)	33.5 (30.0-37.1)	67.0	56.7	45.7	37.2	34.5
	Systemic therapy
		Elderly	22.3 (13.5-31.1)	25.3 (20.6-30.0)	63.2	49.1	31.6	16.8	14.1
		Non-elderly	25.4 (18.3-32.5)	26.3 (21.4-31.2)	59.3	51.2	37.0	26.5	24.5

Values are presented as number (95% confidence interval).

HCC, hepatocellular carcinoma; IPTW, inverse probability of treatment weighting; BCLC, Barcelona Clinic Liver Cancer.